More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Quizartinib [950769-58-1]

Quizartinib [950769-58-1]

Research Use Only
Q8139
LKT Laboratories
Estimated Purity≥98%
Product group Chemicals
€ 778,00
25 mg
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    LKT Laboratories
  • Product Name
    Quizartinib [950769-58-1]
  • Delivery Days Customer
    7
  • Certification
    Research Use Only
  • Estimated Purity
    ≥98%
  • Scientific Description
    FLT3, c-Kit, PDGFR inhibitor.; AC220, AC-220
  • Storage Instruction
    -20°C
  • UNSPSC
    12352200

References

  • Ostronoff F, Estey E. The role of quizartinib in the treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2013 Sep 26. [Epub ahead of print]. PMID: 24070241. Bhullar J, Natarajan K, Shukla S, et al. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions. PLoS One. 2013;8(8):e71266. PMID: 23967177. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, et al. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer. 2013 Mar 7;12:19. PMID: 23497317. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009 Oct 1;114(14):2984-92. PMID: 19654408.